Careers

Diversity

With 17 offices, from New York to Los Angeles and Seattle to Orlando, we live and work in communities all over the U.S., collaborating across locations, disciplines and even borders. Our experienced, highly ranked lawyers serve businesses wherever they are and wherever they want to go.

Offices

About Us

Pages

Professionals

Thought leadership: blogs, podcasts, videos, publications, events and news

Insights

Services

Pro Bono

Am Law 100 firm with practices in Business, Digital Assets and Data Management, Intellectual Property, Labor & Employment, Litigation and Tax.

Home | BakerHostetler

Civil price-fixing case may shed light on whether plaintiffs can win where the DOJ has lost

Four decades after AT&T was broken up, is Google headed down that dark road?

AD Nauseam

AD Nauseam: A Very Special AD Nauseam – Back to School

Carpenter explores carbon credit ‘conundrum’ companies face

On Nov. 25, 2022, Pink Sheet published an article titled “Clinical Trial Diversity Would Benefit from Regulatory, Financial Incentives, Experts Say,” and the piece referenced remarks Partner Winston Kirton gave at a recent Food and Drug Law Institute conference.  Kirton told conference attendees that improving trial diversity from the beginning of drug development through commercialization is not simply a social issue. “It will provide better data to regulators,” he said. Furthermore, while it would be nice if greater diversity happened on its own, “We live in a society and in a country where incentives matter.”  <a href="https://pink.pharmaintelligence.informa.com/PS147296/Clinical-Trial-Diversity-Would-Benefit-From-Regulatory-Financial-Incentives-Experts-Say" target="_blank" rel="noopener">Read the article (subscription required).</a>

core/freeform

Washington, D.C.

Partner

Winston S. Kirton

Business

Winston Kirton Says Greater Clinical Trial Diversity Is Good Business, Should Be Incentivized

Related Services

Featured Insights